STXBP1: fast-forward to a brighter future - a patient organization perspective

Area of Science:

• Neuroscience
• Genetics
• Rare Diseases

Background:

• Syntaxin-binding protein 1 related disorder (STXBP1-RD) is a rare neurologic condition.
• It is characterized by global neurodevelopmental delay, intellectual disability, early-onset epilepsy, motor abnormalities, and autism.
• Pathophysiology involves de novo mutations in the STXBP1 gene, leading to impaired neurotransmitter release and neuronal dysfunction.

Purpose of the Study:

• To support families affected by STXBP1-RD.
• To accelerate the development of effective therapies and a cure for STXBP1-RD.
• To advance understanding of STXBP1-RD through research and strategic initiatives.

Main Methods:

• Initial research focused on understanding disease presentation and developing disease models.
• The STXBP1 Foundation launched the STXBP1 Fast Forward Strategic Plan in 2023.
• Current efforts include a prospective natural history study and biomarker work.

Main Results:

• The STXBP1 protein is crucial for synaptic vesicle fusion and neurotransmitter release.
• Pathogenic STXBP1 variants typically cause haploinsufficiency, affecting neuronal communication.
• Research is progressing to characterize STXBP1 function and disease pathogenicity.

Conclusions:

• STXBP1-RD is a complex genetic disorder requiring further research.
• The STXBP1 Foundation's strategic plan aims to drive precision therapy development.
• Continued research and biomarker studies are essential for advancing treatment options.